INBX - NASDAQ
Inhibrx Biosciences, Inc.
$95.22
+1.7%Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
At a Glance
Live SnapshotInhibrx Biosciences, Inc. Management Team
Dr. Carlos Bais Ph.D.
EVice President & Chief Scientific Officer
Dr. Josep Garcia Ph.D.
Executive Vice President & Chief Clinical Development Officer
Dr. Ashraf Amanullah Ph.D.
Executive Vice President & Chief Technical Operations Officer
Ms. Kelly Devine Deck B.S., CPA, M.S.
Executive Vice President, Chief Financial Officer & Treasurer
Compensation
$2,190,588
Mr. Mark Paul Lappe
Founder, Chief Executive Officer & Chairman
Compensation
$1,130,194
Mr. David J. Matly M.B.A.
President and Chief Commercial & Business Development Officer
Ms. Bonne Adams M.B.A.
Vice President of Operations
Ms. Leah Pollema J.D.
Vice President, General Counsel & Corporate Secretary
Inhibrx Biosciences, Inc. Insider Positioning
During the last 12 months, insiders have sold $9.95M worth of INBX shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
308.6K
9.95M
-10.0M
-$9.95M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Viking Global Investors Lp
10 Percent Owner
$9.95M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $9.95M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
1 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
INBX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 23, 2026 | December 31, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 16, 2025 | December 31, 2024 | 2024 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.